论文部分内容阅读
目的:观察参芪白血饮对缓解期急性白血病患者血清可溶性白细胞介素-2受体(sIL-2R)、肿瘤坏死因子-α(TNF-α)的影响。方法:将40例急性白血病缓解期患者随机分为治疗组和对照组。对照组采用常规巩固化疗方案;治疗组在对照组治疗基础上,予以参芪白血饮口服。治疗4周。用酶联免疫吸附法检测2组治疗前后外周血血清sIL-2R、TNF-α水平的变化。结果:治疗组治疗后sIL-2R、TNF-α水平较治疗前下降,差异有统计学意义(P<0.01);对照组治疗前后sIL-2R、TNF-α比较,差异无统计学意义(P>0.05)。治疗后2组sIL-2R、TNF-α水平比较,治疗组均低于对照组,差异有统计学意义(P<0.05)。治疗组AML及ALL患者治疗后的sIL-2R、TNF-α水平均较治疗前下降,差异有统计学意义(P<0.01,P<0.05)。对照组AML及ALL治疗前后sIL-2R、TNF-α水平比较,差异均无统计学意义(P>0.05)。结论:参芪白血饮可降低缓解期急性白血病患者血清sIL-2R和TNF-α水平,从而可能通过两种因子的免疫调节机制,增强对缓解期患者微小残留白血病细胞的抑制或杀伤,减少复发。
Objective: To observe the effect of Shen Qi Bai Xue Yin on serum soluble interleukin-2 receptor (sIL-2R) and tumor necrosis factor-α (TNF-α) in acute leukemia patients. Methods: Forty patients with acute leukemia remission were randomly divided into treatment group and control group. The control group using conventional consolidation chemotherapy; treatment group in the control group based on the treatment, to be Shenqi Bai Xue Yin. Treatment for 4 weeks. Serum sIL-2R and TNF-α levels were measured by enzyme-linked immunosorbent assay before and after treatment. Results: The levels of sIL-2R and TNF-αwere significantly lower than those before treatment in the treatment group (P <0.01). There was no significant difference in the levels of sIL-2R and TNF-α before and after treatment in the control group (P > 0.05). After treatment, the levels of sIL-2R and TNF-α in the two groups were significantly lower than those in the control group (P <0.05). The levels of sIL-2R and TNF-α in AML and ALL patients after treatment were significantly lower than those before treatment (P <0.01, P <0.05). The levels of sIL-2R and TNF-α in control group before and after AML and ALL treatment showed no significant difference (P> 0.05). Conclusion: Shenqi Baoxue Decoction can reduce the levels of sIL-2R and TNF-α in serum of acute leukemia patients during remission, which may enhance the inhibition or killing of minimal residual leukemia cells in remission patients and reduce relapse by immunomodulatory mechanism of two factors .